# Steroid legality in spain

Marcel Bonn-Miller, ., of the VA National Center for PTSD will serve as Coordinating Principal Investigator, and Paula Riggs, ., of the University of Colorado, Denver will serve as Senior Scientific Advisor. Blood analysis will be conducted at the University of Colorado, Boulder. MAPS will be responsible for FDA approval, project and data management and monitoring, drug accountability, and ensuring Good Clinical Practice (GCP) guidelines are followed throughout the study. “It is a major triumph that we have built this outstanding team of top researchers, partnering with national experts at the VA, NIDA, Johns Hopkins, and the University of Colorado,” said MAPS executive director Rick Doblin, . “The obstacles we’ve faced have ultimately strengthened the study.” Learn more | Read the RFA

A total of 32 healthy male volunteers (age range 20-30 years) were enrolled in a 1-week open, randomized, placebo-controlled study comparing finasteride (Proscar), a 5 alpha-reductase inhibitor, with Permixon, the plant extract of Serenoa repens. The objective of the study was to evaluate the effect of single and multiple doses of the drugs on the inhibition of 5 alpha-reductase as assessed by serum dihydrotestosterone level determination. Following baseline measurements on day 1, the subjects were randomized to finasteride 5 mg once a day (n = 10), Permixon 80 mg x 2 twice a day (n = 11), or to placebo once a day (n = 11) for 7 days. Serum testosterone and dihydrotestosterone levels, were determined on day 1 (baseline and 12 h) and on days 2 (24 h), 3 (48 h), 4 (72 h), 6 (120 h), and 8 (168 h). After 12 h, a single dose of finasteride 5 mg reduced the serum dihydrotestosterone level by 65% (p = ). The decreases ranged from -52 to -60% with multiple doses of finasteride 5 mg once a day (p = ). As in the placebo group, there was no effect of Permixon on the serum dihydrotestosterone level. No significant difference was detected between finasteride and Permixon or between finasteride and placebo with respect to serum testosterone , except on days 3 and 6, respectively (p = ). However, the corresponding serum testosterone levels remained within the normal ranges.

The amphetamine mix branded Adderall is terribly expensive to obtain even compared to modafinil, due to its tight regulation (a lower schedule than modafinil), popularity in college as a study drug, and reportedly moves by its manufacture to exploit its privileged position as a licensed amphetamine maker to extract more consumer surplus. I paid roughly $4 a pill but could have paid up to$10. Good stimulant hygiene involves recovery periods to avoid one’s body adapting to eliminate the stimulating effects, so even if Adderall was the answer to all my woes, I would not be using it more than 2 or 3 times a week. Assuming 50 uses a year (for specific projects, let’s say, and not ordinary aimless usage), that’s a cool \$200 a year. My general belief was that Adderall would be too much of a stimulant for me, as I am amphetamine-naive and Adderall has a bad reputation for letting one waste time on unimportant things. We could say my prediction was 50% that Adderall would be useful and worth investigating further. The experiment was pretty simple: blind randomized pills, 10 placebo & 10 active. I took notes on how productive I was and the next day guessed whether it was placebo or Adderall before breaking the seal and finding out. I didn’t do any formal statistics for it, much less a power calculation, so let’s try to be conservative by penalizing the information quality heavily and assume it had 25%. So 200 − 0 ln × × = 512 \frac{200 - 0}{\ln } \times \times = 512 ! The experiment probably used up no more than an hour or two total.